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Objective: To evaluate the effectiveness of deep brain stimulation (DBS) of the globus pallidus internus
(GPi) on tic severity and common comorbidities in patients with severe Tourette syndrome that is re-
fractory to pharmacological treatment and psychotherapy.
Patients and Methods: We retrospectively assessed the long-term clinical outcomes of 13 patients with
treatment-refractory Tourette syndrome who underwent DBS targeting the GPi at the Beijing Tiantan
Hospital from January 1, 2006, through May 31, 2013. The primary outcome was a change in tic severity
as measured by the Yale Global Tic Severity Scale, and the secondary outcome was a change in associated
behavioral disorders and mood as measured by the Gilles de la Tourette SyndromeeQuality of Life Scale
assessment.
Results: Compared with baseline, the mean reduction in the total Yale Global Tic Severity Scale scores at
last follow-up (mean, 41.9 months; range, 13-80 months) was 52.1% (range, 4.3%-83.6%), and the mean
improvement rates at 1 month, 6 months, 12 months, 18 months, 24 months, 30 months, and 36 or more
months were 11.8%, 20.0%, 26.8%, 36.7%, 44.7%, 49.0%, and 56.7%, respectively. A paired-sample t test
revealed signiﬁcant improvement of tic symptoms after 6 months of DBS programming (P<.05). The Gilles
de la Tourette SyndromeeQuality of Life Scale score improved by a mean of 45.7% (range, 11.0%-77.2%).
Conclusion: This study is currently the largest reported GPi DBS case series of patients with treatment-
refractory TS with the longest follow-up. Our results support the potential beneﬁcial effect of GPi DBS
on disabling tic reduction and improvement of quality of life.ª 2014 Mayo Foundation for Medical Education and Research n Mayo Clin Proc. 2014;89(11):1506-1514T ourette syndrome (TS), a complexneuropsychiatric disorder character-ized by waxing and waning motor
and phonic tics that persist for at least 12
months, begins in childhood and usually di-
minishes in severity around the second decade
of life.1-3 As many as 90% of patients with TS
have comorbid psychiatric conditions such as
obsessive-compulsive disorder or attention-
deﬁcit/hyperactivity disorder.4,5 Patients with
TS, particularly those with mild symptoms,
usually respond to medication and/or psycho-
behavioral treatment, and the condition often
improves during adolescence. In some patients,
however, TS is refractory to medical therapy or
the patient experiences unbearable adverse ef-
fects such as akathisia, dystonia, parkinsonism,
weight gain, hyperprolactinemia, hypotension,
and sedation.6,7 Furthermore, the severity of
tics waxes and wanes over time, whichMayo Clin Proc. n November 2014;89(
www.mayoclinicproceedings.org nnecessitates long-term treatment.1 Therefore,
surgery has been considered as an alternative
treatment for some patients with ongoing
medically refractory disease.8-10
Deep brain stimulation (DBS) of the thal-
amus was introduced as a new surgical tech-
nique for the treatment of intractable TS in
1999.11 Since then, DBS in patients with TS
has received increasing attention and produced
good effects.9,12 To date, approximately 21
medical centers in 12 countries have performed
DBS and found encouraging results in the
decrease of tics; however, the effect on comor-
bidities has been variable.13,14 Seven different
brain targets in the thalamus, pallidum, ventral
caudate, and anterior internal capsule have
reportedly been stimulated.2 However, there
is no consensus on the most appropriate DBS
target site. The centromedian-parafascicular
complex (CM-Pfc) of the thalamus has been11):1506-1514 n http://dx.doi.org/10.1016/j.mayocp.2014.05.019
ª 2014 Mayo Foundation for Medical Education and Research
DEEP BRAIN STIMULATION IN TOURETTE SYNDROMEreported to be themost frequently used target for
TS DBS. In addition, the pathophysiology of TS
was found to be related to the defect in the cor-
ticalebasal gangliaethalamocortical neuronal
circuitdspeciﬁcally, the globus pallidus internus
(GPi) could be the primary output nucleus of the
basal ganglia to the thalamus, and its stimulation
modulates the basal ganglia-thalamocortical
loop.14,15 Consequently, a pilot study of 3 Italian
patients found that bilateral stimulation of the
GPi produced a more favorable outcome in tic
severity (78% reduction) than stimulation of
the thalamic CM-Pfc (45% reduction).16 Recent
case series of 5 European patients17 and 11
Australian cases18 also documented similar clin-
ical beneﬁts of GPi DBS in patients with TS.
However, most of those cases had follow-up
times of less than 2 years. Conversely, a compli-
cating issue of GPi target is the differential
anatomic-functional distribution of both motor
and limbic circuits throughout the GPi, the
limbic region lying anteromedial while themotor
region is located posterolateral and inferior, with
some considerable distance between them.17
In this study, we retrospectively assessed the
clinical outcomes and the long-term (13-80TABLE 1. Clinical Characteristics of the Study Population
Patient Tic symptoms
Assoc
1 Eye blinking, head banging, shoulder shrugs,
leg jerks, facial grimaces None
2 Facial grimaces, shoulder shrugs, arm
ﬂexion, shouting, coprolalia None
3 Shoulder shrugs, grunting, echolalia None
4 Echolalia OCD
5 Head banging, shoulder shrugs, shouting None
6 Head banging, shoulder shrugs, shouting None
7 Head banging, neck extension None
8 Facial grimaces, shoulder shrugs, arm
ﬂexion, shouting, coprolalia
OCD
9 Shoulder shrugs, shouting ADH
10 Eye blinking, coughing, head banging,
shouting, bird noises None
11 Eye blinking, coughing, head banging,
shouting None
12 Head banging, shoulder shrugs, neck
extension, coprolalia, shoulder elevation
OCD
13 Eye blinking, head banging None
aADHD ¼ attention-deﬁcit/hyperactivity disorder; bid ¼ twice a day;
bAll patients had treatment failure with a-adrenergic agonists, 2 or m
Mayo Clin Proc. n November 2014;89(11):1506-1514 n http://dx.do
www.mayoclinicproceedings.orgmonths) follow-up results in 13 Chinese pa-
tients with TS who underwent DBS targeting
the GPi, speciﬁcally the posterolateral region.
We evaluated the effect of DBS on tic severity
and the effect on quality of life and functional
outcomes.PATIENTS AND METHODS
Study Population
We retrospectively assessed the long-term clin-
ical outcomes of 13 patients with treatment-
refractory Tourette syndrome who underwent
DBS targeting the GPi at the Beijing TiantanHos-
pital from January 1, 2006, through May 31,
2013. The study was approved by the ethics
committee at Beijing Tiantan Hospital. The pa-
tients (12 males and 1 female) had undergone
GPi DBS because of the severe disability arising
from their tics (Tables 1 and 2). In all 13 pa-
tients, a-adrenergic agonists, 2 or more dopa-
mine receptor antagonists, benzodiazepine,
and behavioral therapy had failed.5 Preopera-
tively, each of these patients was evaluated by
specialists and identiﬁed as fulﬁlling the Diag-




At DBS surgery 1 y after surgery




Yes Haloperidol, 4 mg bid Haloperidol, 4 mg bid
Yes Haloperidol, 4 mg bid;
pimozide, 4 mg/d
None
Yes Haloperidol, 4 mg bid None
, ADHD No Haloperidol, 4 mg bid;
pimozide, 4 mg/d
Haloperidol, 4 mg bid
D No None None
Yes None None
Yes None None
, ADHD No Risperidone, 2 mg bid;
mirtazapine, 45 mg bid;
citalopram, 40 mg/d
Risperidone, 2 mg bid;
mirtazapine, 45 mg bid;
citalopram, 40 mg/d
No None None
DBS ¼ deep brain stimulation; OCD ¼ obsessive-compulsive disorder.
ore dopamine receptor antagonists, benzodiazepine, and behavioral therapy before DBS surgery.
i.org/10.1016/j.mayocp.2014.05.019 1507











target Surgical complications Adverse effects Follow-up (mo)
1 M 8 16 C None GPi None None 80
2b M 9 19 C S GPi Pyosis on head None 60
3 M 13 20 S S GPi Chest subcutaneous
hydrops
Anxiety 53
4 M 3 18 S S GPi None None 54
5 M 11 20 C S GPi None None 57
6b M 10 28 C S GPi None None 54
7b F 20 21 C None GPi None None 47
8 M 12 18 C S GPi None Agitation 38
9 M 10 17 C S GPi None Agitation 36
10 M 6 34 C S GPi None None 14
11 M 13 28 C S GPi None Anxiety 22
12b M 7 23 C C GPi None Anxiety, agitation,
depression, tiredness
17
13 M 7 20 C None GPi None None 13
aC ¼ complex; DBS ¼ deep brain stimulation; F ¼ female; GPi ¼ globus pallidus internus; M ¼ male; S ¼ simple.
bImplants were removed in patients 2, 6, 7, and 12 for various reasons between 1 week and 5 years after surgery.
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1508(Fourth Edition) criteria for TS19 and was ap-
proved for the DBS procedure by the neuromo-
dulation committee at Beijing Tiantan Hospital.
Preoperatively, and again after optimization of
DBS parameters, each patient was tested with
the Yale Global Tic Severity Scale (YGTSS)
(Supplemental Table 1, available online at
http://www.mayoclinicproceedings.org).5,20 The
YGTSS score of 35 (motor and vocal tic severity
on a scale of 0-50) or higher for 1 year is a
marker of disease severity sufﬁcient to warrant
consideration for DBS. All patients had severe
tic disorder with functional impairment and
YGTSS scores higher than 35. In addition, tics
were the major symptom causing disability in
all patients, and their comorbid conditions
were stable with treatment.Target, Surgery, and Stimulation
All patients underwent DBS of the GPi.21 Specif-
ically, the posterolateral region (motor region)
of the GPi was selected to be the target for
DBS (Supplemental Figure, available online at
http://www.mayoclinicproceedings.org). The
target was 3 mm anterior to the mid-
commissural point, 18 to 21 mm lateral to the
midplane of the third ventricle, and 4 to 6 mm
below the intercommissural line. Technical
details of the procedure are presented in
Supplemental Table 2 (available online at
http://www.mayoclinicproceedings.org).Mayo Clin Proc. n November 2014;89(Outcome Measures
Tic assessment was performed before GPi DBS, at
the endof theﬁrstmonth after the procedure, and
every 6 months thereafter. The primary outcome
was the total YGTSS score.20 Tic severity was
considered according to the most intense tic,
even if it only occurred once. All patients under-
went assessment with the Gilles de la Tourette
SyndromeeQuality of Life Scale (TSQOL)22 dur-
ing the postoperative period.Statistical Analyses
The primary outcome was the difference in the
total YGTSS score between the preoperative
assessment and the last postoperative follow-
up assessment. The secondary outcome was
the difference in the total TSQOL score between
the preoperative assessment and the last postop-
erative follow-up assessment. All data were
analyzed using SPSS version 13.0 software
(SPSS Inc). Speciﬁcally, a paired-sample t test
was used to determine whether there was a sig-
niﬁcant difference between the scores at baseline
and follow-up. P<.05 was considered statisti-
cally signiﬁcant.RESULTS
Study Population
Tables 1 and 2 present an overview of the clin-
ical and demographic characteristics of the 1311):1506-1514 n http://dx.doi.org/10.1016/j.mayocp.2014.05.019
www.mayoclinicproceedings.org
TABLE 3. Yale Global Tic Severity Scale Assessments at Sequential Follow-up
Patient
Yale Global Tic Severity Scale scorea
Baseline 1 mo 6 mo 12 mo 18 mo 24 mo 30 mo 36þ mo
Last follow-up
(% improvement)
1 58 43 35 27 30 30 26 24 19 (67.2)
2 61 53 48 37 33 27 24 15 10 (83.6)
3 74 53 47 43 36 33 26 19 17 (77.0)
4 74 65 46 53 38 27 28 26 21 (71.6)
5 47 43 40 35 31 24 21 10 8 (83.0)
6 45 42 43 39 36 32 27 25 18 (60.0)
7 48 45 41 37 33 29 25 23 22 (54.2)
8 93 87 78 67 63 55 67 59 48 (48.4)
9 73 65 67 64 59 55 48 46 46 (37.0)
10 58 53 45 38 ND ND ND ND 35 (39.7)
11 58 51 48 45 43 39 ND ND 36 (37.9)
12 94 94 92 90 ND ND ND ND 90 (4.3)
13 42 34 31 29 ND ND ND ND 25 (40.5)
Mean (SD) 60.9 (15.1) 52.8 (14.1) 47.4 (13.0) 42.8 (12.6) 40.2 (11.6) 35.1 (11.3) 32.4 (15.1) 27.4 (15.5) 25.4 (13.1) (58.3)
Improvement (%)b NA 13.3 22.2 29.7 34.0 42.4 46.8 55.0 58.3
Mean (SD) 63.5 (17.1) 56.0 (17.7) 50.8 (17.6) 46.5 (17.8) 40.2 (11.6) 35.1 (11.3) 32.4 (15.1) 27.4 (15.5) 30.4 (21.8) (52.1)
Improvement (%) NA 11.8 20.0 26.8 36.7 44.7 49.0 56.7 52.1
aMotor and phonic tic number, frequency, intensity, complexity, and interference are scored 0-5 each, and the overall impact of tics on activities is scored 0-50. The total is
thus in the 0-100 range. The improvement rate was the Yale Global Tic Severity Scale scores at last follow-up compared with baseline of all patients.
bPatient 12 was excluded in the calculation of improvement rates because his electrodes were explanted 1 week after implantation.
TABLE 4. Comparison of Gilles de la Tourette SyndromeeQuality of Life Scale
(TSQOL) Scores at Baseline and at Last Follow-upa
Patient
TSQOL score
Baseline (overall) Last follow-up Improvement (%)
1 48 21 56.3
2 53 15 71.7
3 58 27 53.4
4 55 33 40.0
5 57 13 77.2
6 48 18 62.5
7 43 21 51.2
8 68 42 38.2
9 49 35 28.6
10 43 27 37.2
11 54 31 42.6
12 73 65 11.0
13 43 28 34.9
Mean 53.2 28.9 45.7
aThe TSQOL was transformed to a 0-100 range (lower scores reﬂecting better quality of life).
DEEP BRAIN STIMULATION IN TOURETTE SYNDROMEpatients. The mean (SD) age at DBS was 21.7
(5.0) years (range, 16-34 years). The duration
of disease ranged from 1 to 28 years (mean
[SD], 11.8 [6.6] years). Eight of the 13 patients
were younger than 21 years of age at the time of
implantation. The YGTSS scores at the last visit
compared with baseline were reduced in all 13
patients. Table 3 presents quantitative results of
YGTSS assessments for each patient at sequen-
tial follow-up visits. Table 4 presents quantita-
tive results of TSQOL assessments at the last
follow-up. We excluded patient 12 from these
analyses because his electrodes were explanted
1 week after implantation.
Electrode Localization and Stimulation
Settings
We used Medtronic 3387 electrodes, each of
which has 4 contacts at the distal tip con-
ventionally named 0 through 3 for the left
hemisphere and 4 through 7 for the right hemi-
sphere; site, voltage, pulse width, and frequency
of stimulation can be controlled by external pro-
gramming through an implanted battery. Usu-
ally, it took us as long as 6 months before
optimal stimulating settings were identiﬁed
(Supplemental Table 2, available online at
http://www.mayoclinicproceedings.org). MostMayo Clin Proc. n November 2014;89(11):1506-1514 n http://dx.do
www.mayoclinicproceedings.orgof our patients had a double monopolar conﬁg-
uration with 02/Cþ and 46/Cþ, while
several other patients had monopolar (1/Cþ
and 5/Cþ) and bipolar (13þ and 57þ)
conﬁgurations, all with a bilateral amplitude of
3.6 V or less, pulse width of 120 ms or less,

















FIGURE. Mean total Yale
13 study patients at var




The mean (SD) YGTSS score was 63.5 (17.1)
(range, 42-94) at baseline and 30.4 (21.8)
(range, 8-90) at last follow-up (mean, 41.9
months; range, 13-80 months) with a mean
reduction of 52.1% (range, 4.3%-83.6%).
The mean improvement rates at 1 month, 6
months, 12 months, 18 months, 24 months,
and 36 months after DBS were 11.8%,
20.0%, 26.8%, 36.7%, 44.7%, 49.0%, and
56.7%, respectively, over baseline (Table 3,
Figure). Additionally, the motor and vocal tic
severity scores (on a scale of 0 to 50) improved
from 18.0 and 10.7, respectively, before DBS
to 11.0 and 6.0, respectively, at the last
follow-up (Supplemental Table 2, available
online at http://www.mayoclinicproceedings.
org). Notably, 5 patients (patients 1, 2, 4, 8,
and 9), all of whom were younger than 20 years
of age at the time of DBS implantation, had
excellent post-DBS outcomes (the mean YGTSS
improvement rate was 61.6% [range, 37.0%-
83.6%]). The mean TSQOL score of the study
group was 53.2 (range, 43-73) preoperatively
and 28.9 (range, 13-65) postoperatively, with
a mean reduction of the TSQOL score of
45.7% (range, 11.0%-77.2%; Table 4). Almost
all patients had signiﬁcant improvement in
well-being as assessed by the TSQOL scale
(paired-samples t test, P<.05). Taken together,
our study results revealed that almost all patients
had a reduction of YGTSS scores and signiﬁcant
improvement of the tics (P<.05). The YGTSS mo 12 mo 18 mo 24 mo 30 mo 36+ mo
* * * * * *
Global Tic Severity Scale (YGTSS) scores of the
ious time points before (baseline) and after deep
ars indicate standard deviation of YGTSS scores.
Mayo Clin Proc. n November 2014;89(improvement was noticed at 6 months after
DBS surgery (P<.05; Table 3). Furthermore, 9
of the 13 patients found jobs and were able
to ﬁnancially support their families. Comorbid
psychiatric symptoms remained stable or
slightly improved in almost all patients accord-
ing to the consulting psychiatrists, and most pa-
tients attained a self-reported higher level of
social functioning.
Surgical Accuracy, Complications, and
Adverse Effects of Stimulation
No immediate complications were reported in
our patients. Patient 2 had pyosis on his head
2 years after the operation. Notably, his symp-
toms almost completely resolved, and he has
attained a self-reported higher level of social
functioningdin fact, he became engaged and
then got married. At the patient’s request, we
removed his battery, electrode, and the exten-
sion cables 5 years after the operation. To date,
he has not reported recurrence of any symp-
toms. In patient 12, the DBS electrodes were
removed 1 week after implantation because of
the absence of clinical beneﬁt during the pro-
gramming and persistent requests from the pa-
tient and his family. Patients 6 and 7 underwent
removal of the implant electrodes 4 years after
DBS; both patients have sustained substantial
beneﬁt from the procedure and report having
“a normal life.” Patient 3 experienced subcu-
taneous hydrops and signs of infection on the
chest 3 years postoperatively. Unsurprisingly,
some patients experienced mood disordersd
patients 3 and 11 reported anxiety, and patients
8 and 9 had agitation. However, these symptoms
can be resolved with careful programming. Pa-
tient 12 experienced anxiety, agitation, depres-
sion, and constant tiredness that did not
respond to stimulation adjustment, and therefore
his electrodes were removed.
DISCUSSION
This study is the largest reported case series of
patients with treatment-refractory TS who un-
derwent GPi DBS with the longest follow-up
data (mean, 41.9months; range, 13-80months).
All but one of the 13 patients reported an
improvement in tic severity and quality of life af-
ter DBS, with an overall 52.1% reduction in total
tic severity relative to baseline. Speciﬁcally, 6 pa-
tients (patients 1-6) reported a dramatic response
with almost complete cessation of moderate to11):1506-1514 n http://dx.doi.org/10.1016/j.mayocp.2014.05.019
www.mayoclinicproceedings.org
DEEP BRAIN STIMULATION IN TOURETTE SYNDROMEsevere tics and an overall marked reduction in all
tic types. Notably, 9 of 13 patients found jobs
and were able to ﬁnancially support their fam-
ilies. Eight patients were younger than 21 years
of age at the time of surgery. Five of them (pa-
tients 1, 2, 4, 8, and 9), all of whom were
younger than 20 years of age at the time of
DBS implantation, had excellent post-DBS out-
comes (the mean YGTSS improvement rate was
61.6% with a range of 37.0%-83.6%). Further-
more, comorbid psychiatric symptoms have
remained stable or slightly improved in all pa-
tients according to the consulting psychiatrists,
and almost all patients attained a self-reported
higher level of social functioning. The results of
our case series indicate that GPi DBS is a safe
and effective treatment in Chinese patients with
treatment-refractory TS. These results are impor-
tant because they provide further evidence that
DBS is an effective treatment option for a sub-
group of patients with TS who have no other op-
tion available. Furthermore, it appears that GPi
DBS has a sustained impact on both tic severity
and overall quality of life and further reduces
the adverse effects and cost of long-term
medications.
So far, 7 separate brain targets have been
used in TS DBS. However, there is no consensus
on the most appropriate DBS target site. It has
been reported that the GPi is the main output
regulator of the basal ganglia and might
contribute to motor function and behavior con-
trol in patients with TS. In addition, in several
pilot studies, GPi DBS produced a better
outcome than stimulation of other tar-
gets.17,18,23 However, none of these studies
had a randomized double-blind design.
Recently, the effectiveness of DBS of the antero-
medial GPi (limbic region) on tic severity and
common comorbidities was assessed in 11
Australian patients with severe TS who had a
mean follow-up of 14 months (range, 4-30
months).18 Ten patients (90.9%) reported
improvement in tic severity soon after DBS,
with an overall 48% reduction in motor tics at
ﬁnal follow-up. Our results of a 52.1% reduc-
tion in total tic severity in 13 patients with severe
TS who had longer follow-up (mean, 41.9
months; range 13-80 months) indicate remark-
able potential long-term beneﬁts of DBS in difﬁ-
cult cases and particularly the optimal target of
posterior lateral (motor region) GPi in DBS sur-
gery.24-27 Furthermore, the target varied in theMayo Clin Proc. n November 2014;89(11):1506-1514 n http://dx.do
www.mayoclinicproceedings.orglaterality of electrode placement in our
study.16,28-30 Typically, the target was 18 to 21
mm lateral to themidplane of the third ventricle.
It is plausible that an electrode placed at 18 mm
from midline will yield more limbic effects than
one placed at 21 mm, but further study is
needed to conﬁrm this hypothesis. Whether
target selection is related to postoperative tic
control and mood disorders should also be
investigated. Most case series have reported
wide variability in stimulation parameters, with
amplitudes varying from 2 to 5 V, frequencies
between 130 and 210 Hz, and pulse widths
from 60 to 210 ms.13,16,30-33 Monopolar, bipo-
lar, and double monopolar stimulation parame-
ters have been used in reported series, and the
choice of optimal contact inevitably depended
on precise electrode location. In our study, it
took us as long as 6 months before optimal stim-
ulating settings were identiﬁed. In some pa-
tients, even more time is needed for program
adjustment. As indicated in Table 3, patient 6
had minimal improvement in YGTSS scores at
6-month follow-up, but with further DBS pro-
gram optimizing, he eventually had a good
response. Most of our patients had a double
monopolar conﬁguration with 02/Cþ and
46/Cþ, while several other patients had
monopolar (1/Cþ and 5/Cþ) and bipolar
(13þ and 57þ) conﬁgurations, all with
bilateral amplitudes of 3.6 V or less, pulse
widths of 120 ms or less, and rates of 185 Hz
or less. During the ﬁrst year of follow-up, most
patients visited our DBS clinic 3 to 5 times for
parameter adjustment and had a steady effect
for approximately 1 year after the operation.
During the subsequent 2 to 3 years, patients
visited us 1 to 2 times, mainly for increasing
the parameters of voltage and frequency. After
that, patients rarely needed any further pro-
gramming adjustment. Certainly, the potential
beneﬁts of a double monopolar conﬁguration
setting in TS DBS, particularly in Chinese pa-
tients, might need to be further explored.
Notably, Okun et al9 recently reported that
scheduled stimulation, rather than the classic
continuous DBS paradigm, had potential to
improve motor and vocal tics in patients with
TS who underwent DBS targeting the centrome-
dian thalamic region. In our study, we used only
continuous programming. We believe that in
the future, scheduled stimulation should also
be tested in patients with TS who undergo GPii.org/10.1016/j.mayocp.2014.05.019 1511
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1512DBS. Conversely, simultaneous modulation of
motor and associative-limbic targets/networks
may be more efﬁcacious than singleetarget/
network stimulation. Simultaneous stimulation
of motor and limbic areas of the GPi have been
reported to improve behavioral disorders in
Lesch-Nyhan syndrome.34 An altered interaction
between the limbic and motor circuits is thought
to be responsible for the clinical manifestations in
TS. As such, it is worthwhile to investigate
whether the simultaneous stimulation of pallidal
limbic and motor territories could be the most
effective treatment for TS.
The adverse events associated with DBS in
our series were mild and uncommon, with the
exception that 2 patients (cases 2 and 3) had in-
fections. This low rate of complications is similar
to that in our experience with DBS for all other
indications. However, 3 patients (cases 2, 6,
and 7) had their hardware removed between
the fourth and ﬁfth year after the DBS operation.
Speciﬁcally, patient 2 had the best beneﬁcial ef-
fects (YGTSS score improvement of 83.6%),
and his symptoms almost completely resolved.
Regarding patients 6 and 7, although their
YGTSS score improvements were 60.0% and
54.2%, respectively, at the latest follow-up,
both of them thought that DBSwas not beneﬁcial
at all, and therefore the hardware was removed.
We found that most Chinese patients do not
like having anything nonessential implanted in
their bodies. Moreover, as patients grow up and
their symptoms get better, they and their families
believe that the implants are no longer necessary.
In addition, Schüpbach et al35 reported that after
DBS stimulation, patients experience difﬁculties
in their relationships with themselves, their
spouses, their families, and their socioprofes-
sional environments. These authors suggested a
multidisciplinary psychosocial preparation and
follow-up to help patients and their families
and friends cope with the changes experienced
after successful neurosurgery. OurDBS implanta-
tion and programming signiﬁcantly improved
the tic symptoms and helped all 3 patients to
resume normal life postoperatively. Currently,
all of them are clinically stable with mild symp-
toms, but this improvement could also be related
to the symptom diminishment that characteristi-
cally occurs during the second decade of life in
patients with TS. Additionally, patient 12 had
very severe tics and self-injury (YGTSS score,
94). He had not responded to all availableMayo Clin Proc. n November 2014;89(medications and psychobehavioral therapy. In
order to avoid self-injury tics, this patient under-
went DBS with the agreement of the Neuromo-
dulation Committee after weighing the beneﬁts
vs the risks. Unfortunately, his DBS electrodes
were removed 1 week after implantation because
of the absence of clinical beneﬁt during the pro-
gramming and persistent requests from the pa-
tient and his family.
Because TSmay spontaneously remit during
adolescence, early recommendations for patient
selection have indicated that DBS be reserved for
those at least 25 years of age,5,36 20 years old,28
or 18 years old.31 Patient selection for our study
was synthesized from criteria used in clinical
studies and recommendations from the litera-
ture.5,28,31,36,37 However, severe TS in late
adolescence can be disruptive to development,
often jeopardizing educational opportunities,
and some tics are of sufﬁcient severity to raise
concern for self-injury. For these reasons,
some of the largest series have included patients
as young as 17 or 18 years old,31,38 and more
recently published guidelines concede that there
is not yet a consensus among experts.39 Notably,
our study may now be the largest series of DBS
for TS in patients younger than age 21 (8 pa-
tients) in the literature. We also found that 5
of our 13 patients, all of whom were younger
than 20 years of age at the time of DBS implan-
tation, had excellent post-DBS outcomes (mean
YGTSS improvement rate, 61.6%; range,
37.0%-83.6%). Although it is preferable to delay
DBS as long as possible to allow for possible
spontaneous improvement, we believe that tic
severity must be a consideration when selecting
candidates for the procedure. Younger patients
could obtain beneﬁts and a higher level of social
functioning earlier. They will have more chances
to successfully enroll in school, ﬁnd jobs, and
support their families. Based on our experience
and other published evidence, we support the
indication for GPi DBS in severe medically
intractable TS (without dystonia) in patients
who are younger than 20 years of age and expe-
rience progressive comorbidity as a result of
their tics. It is important that the local ethics
committee be consulted for consideration of pa-
tients younger than 18 years of age.40,41
The main limitation of our study is its retro-
spective design necessitated by ethical issues,
and in the future, a crossover study should
enable us to evaluate the differential effect of11):1506-1514 n http://dx.doi.org/10.1016/j.mayocp.2014.05.019
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the ventromedial part of the GPi. In addition,
3 of our 13 patients had their hardware removed
at 4 to 5 years after DBS implantation, which
might be due to cultural and socioprofessional
environmental issues; however, all of them did
obtain signiﬁcant beneﬁt during the DBS pro-
gramming. Patient 12 had his implant removed
1 week after DBS surgery because of lack of efﬁ-
cacy and persistent requests from the patient
and his family.CONCLUSION
This long-term follow-up study of 13 patients
with TS further supports the beneﬁcial effect of
GPi DBS on tic reduction and quality of life,
particularly in patients younger than 21 years
of age. However, symptoms of TS can also spon-
taneously improve during adolescence. There-
fore, it is worthwhile to compare the YGTSS
scores of our study population who were
younger than 21 years of age at the time of
DBS implantation to a cohort of age-matched
patients who did not undergo DBS. The results
of such a study would provide further evidence
for GPi DBS in younger patients with TS.SUPPLEMENTAL ONLINE MATERIAL
Supplemental material can be found online at
http://www.mayoclinicproceedings.org.Abbreviations and Acronyms: CM-Pfc = centromedian-
parafascicular complex; DBS = deep brain stimulation; GPi =
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YGTSS = Yale Global Tic Severity Scale
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